This inventor holds 1 USPTO granted patent and 17 published patent applications. Top assignee: Aging Wise Biotechnology, Inc.. Active years: 2017.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2017
Title: Innovations in Dementia Detection by Rui Lu
Introduction
Rui Lu is an accomplished inventor based in Shanghai, China. He has made significant contributions to the field of medical diagnostics, particularly in the early detection of senile dementia. His innovative approach focuses on utilizing specific biomarkers to enhance diagnostic accuracy.
Latest Patents
Rui Lu holds a patent for the invention titled "Use of TRPC6 mRNA levels in peripheral blood cells for early detection/diagnosis of senile dementia." This invention relates to the use of TRPC6 mRNA levels in peripheral blood cells for the early detection and diagnosis of senile dementia. Specifically, it provides a classic transient receptor potential channel 6 (TRPC6) gene or protein and its application in preparing a reagent or test kit for detecting or diagnosing Alzheimer's disease. Furthermore, the invention includes a polypeptide used to prepare a medicament that treats Alzheimer's disease, along with a composition of said polypeptide. He has 1 patent to his name.
Career Highlights
Rui Lu is currently associated with Aging Wise Biotechnology, Inc., where he continues to work on innovative solutions in the field of aging and dementia. His research and inventions aim to improve the quality of life for individuals affected by neurodegenerative diseases.
Collaborations
Rui Lu collaborates with notable colleagues, including Junfeng Wang and Yizheng Wang, who contribute to his research endeavors and help advance the field of dementia diagnostics.
Conclusion
Rui Lu's work in the early detection of senile dementia through innovative biomarker research represents a significant advancement in medical diagnostics. His contributions have the potential to improve patient outcomes and enhance the understanding of neurodegenerative diseases.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile